March 2016, BlueBee investment
Capital increase to accelerate go-to-market and drive international growth
The Series A financing builds on an exceptional year for Bluebee which saw its customer base growing rapidly, proving strong market momentum and the shift of genome sequencing towards the clinic.
Hans Cobben, CEO of Bluebee, commented: “This is an exciting time for Bluebee. After a successful market introduction in the second half of 2014, and with a rapidly growing customer base, the time is right to shift gears. This funding will significantly boost our capacity to support our growth. We appreciate the continued support ofour existing shareholders, and look forward to working with our new investors.”
“Korys is very excited to be part of a company that will enable the fast-growing genomics discipline to move to the next level by offering data accuracy and throughput performance that will be critical for health-related applications worldwide”, said Vincent Vliebergh, CEO of Korys.
Marc Lambrechts, Senior Investment Manager at Capricorn Venture Partners, added:“We appreciate the strong, interdisciplinary team at Bluebee and the complementary skills of the teams in Delft, The Netherlands and Mechelen, Belgium. In digitalhealthcare the key to success is the integration of knowhow from the ICT world into the healthcare space.”
In addition to the funding round, Bluebee appointed a new chairman of its board ofadvisors: Annie Vereecken, founder and former owner of the AML-Labo Riatol labs,which were sold to Sonic Healthcare Ltd in 2010. Her strong belief in NextGeneration Sequencing and the impact on further development of lab business and clinical practice are the main triggers to join Bluebee, as an investor and as chairman of the advisory board.
Strong market traction
Experts foresee a huge demand for genomics in the next few years. A report byMcKinsey Global Institute expects genetic sequencing to become “standard during medical exams by 2025” requiring substantial industrialisation efforts. Even today,clinical diagnostic applications are the fastest growing segment of the next generation sequencing (NGS) market, as genomics moves from research labs into the clinical environment. The use of genomics on an industrial scale will require technology that is both easy-touse as well as scalable and secure.“When genomics become more standard, clinicians and lab researchers will have less interest in delving into the nuts and bolts of the bioinformatics process, and will expect a secure service that is highly scalable and that just works,” says Hans Cobben. “We enable virtually unlimited scaling up of sequencing capacity while respectingrequirements for localised data processing and storage, which is a first in this industry.”
Bluebee (www.bluebee.com) provides high performance genomics solutions, enabling genomic labs to substantially reduce cost and time-to-diagnosis. Bluebee’s unique cloud-based accelerated genomics platform enables fast, efficient and affordable processing of large volumes of genomics data. With Bluebee’s private-cloud basedsolutions, labs can run their pipelines orders of magnitude faster without compromising the algorithms and methods used, nor the flexibility required to provide quality, sensitivity and reliability.The combination of domain experts in the development and deployment of large scale mission-critical infrastructure, seasoned bioinformaticians and renowned academic researchers in high performance computing, led to the use of three disruptive technologies – high performance computing, cloud computing and genomics – which together deliver a unique genome analytics service for research and clinical labs.